ClinicalTrials.gg
Active, not recruitingNCT04211337LIBRETTO-531Updated Mar 19, 2026Results posted

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

A Phase 3 interventional study of Selpercatinib and Cabozantinib in Medullary Thyroid Cancer, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 143 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.

Enrollment
3rd of 16
291 · median 151
Started
2020
with 1 other
Phase 3
3 of 18
1 open now
Primary completion
2023-05
later than 1 of 10 live
Registered
5th of 18
by date
Lead sponsor
1 of 18
Loxo Oncology, Inc.

Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 5th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Medullary with a site in China, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Read the detailed description

Adaptive sample size re-estimation will be performed at interim analysis. The sample size could be increased from approximately 250 to 400 depending on the results of interim analysis.

03

Conditions studied

  • Medullary Thyroid Cancer

Browse trials for

Keywords

  • medullary thyroid carcinoma
  • targeted therapy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • At least 18 years of age (participants as young as 12 years of age will be allowed if permitted by local regulatory authorities).
  • or cytologically confirmed, unresectable, locally advanced and/or MTC and no prior history of treatment with kinase inhibitors for advanced/metastatic disease.
  • Radiographic progressive disease per (RECIST) 1.1 at screening compared with a previous image taken within the prior 14 months as assessed by the BICR. Participants with measurable or non-measurable but evaluable disease are eligible; however, participants with non- may not have disease limited to bone sites only.
  • A defined/acceptable RET gene alteration identified in a tumor, germline deoxyribonucleic acid (DNA) or blood sample.

    • Tumor tissue in sufficient quantity to allow for retrospective central analysis of RET mutation status
  • performance status score of 0 to 2.
  • Adequate hematologic, hepatic, and renal function and electrolytes.
  • Men and women of must agree to use a highly effective method during treatment with study drug and for 4 months following the last dose of study drug.
  • Ability to swallow capsules.

Exclusion Criteria:

  • An additional validated oncogenic driver in MTC if known that could cause resistance to selpercatinib treatment. Examples include, but are not limited to RAS or BRAF gene mutations and NTRK gene fusions.
  • Symptomatic central nervous system (CNS) metastases, , or untreated spinal cord compression.
  • active cardiovascular disease or history of myocardial infarction within 6 months, history of Torsades de pointes, or prolongation of the >470 milliseconds on more than one (ECG) during screening. Participants who are intended to receive vandetanib if randomized to the control arm are ineligible if QTcF is >450 milliseconds.
  • Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing uncontrolled intercurrent illness.
  • Active hemorrhage or at significant risk for hemorrhage.
  • Other unless nonmelanoma skin cancer, carcinoma in situ or malignancy diagnosed ≥2 years previously and not currently active. Participants with multiple endocrine neoplasia type 2 (MEN2) associated pheochromocytoma may be eligible.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
291 participants (actual)

Study arms

  • Experimental
    Selpercatinib - Treatment A (TRT A)

    160 milligrams Selpercatinib administered orally (PO) twice daily (BID). Adolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID).

    Drug: Selpercatinib

  • Active comparator
    Cabozantinib or Vandetanib - Treatment B (TRT B)

    140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice. Cabozantinib Adolescent Dose: 40 mg/m2. Vandetanib Adolescent Dose: * 0.7 - \<0.9 - 100 mg every other day (QOD) * 0.9 - \<1.2 - 100 mg QD * 1.2 - \<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg * ≥1.6 - 200 QD

    Drug: Cabozantinib · Drug: Vandetanib

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months

Secondary outcomes

  1. Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)

    TFFS by BICR is defined as the time from randomization to the first occurrence of: * documented radiographic disease progression per RECIST 1.1 as assessed by BICR; or * unacceptable toxicity leading to treatment discontinuation as assessed by the investigator. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. To qualify as an event, the toxicity must be from an intolerable AE (defined as any study drug-related AE that meets protocol guidance for treatment discontinuation, with the exception of alopecia); or death (due to any cause).

    Time frame: Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months

  2. Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR

    ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR.

    Time frame: Baseline through Disease Progression or Death Up to 39 Months

  3. Duration of Response (DoR) by BICR

    DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 39 Months

  4. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization until death from any cause. If the participant is alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.

    Time frame: Baseline

  5. PFS2 by Investigator

    Progression-free survival 2 (PFS2) is defined as the time from randomization to disease progression (radiographic or symptomatic progression as determined by the investigator) on the next line of treatment or death from any cause in the absence of observed disease progression. If the participant is alive at the cutoff for analysis, and disease progression has not been observed, PFS2 data will be censored on the latest date of last progression-free assessment or start of the next line of treatment.

    Time frame: Baseline

  6. Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)

    Comparative tolerability defined as a comparison of the proportion of time on treatment with high side effect bother as assessed by the FACT-GP5. The FACT-GP5 is a single question used to assess the overall bother of the treatment side effects. It is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bother from treatment side effects. Time with high side effect bother (i.e.) score of 3 or 4 is reported here and was derived as follows: cumulative amount of time, in weeks, during which a participant reports high side effect bother divided by the total duration of therapy (weeks), derived as (date of last study treatment dose - date of first study treatment dose + 1) divided by 7.

    Time frame: Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months

  7. The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)

    Time frame: Baseline

07

Results

Posted Jun 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneSelpercatinib - Treatment A (TRT A)Cabozantinib or Vandetanib - Treatment B (TRT B)
Started19398
Received at least one dose of study drug19397
Completed1856
Not completed17542
Withdrew: On treatment17540
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryProgression Free Survival (PFS) by Blinded Independent Central Review (BICR)

PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months
Reported as:
Median · Months
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
MonthsSelpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)NA (NA to NA)16.76 (12.22 to 25.10)
Statistical analysis
  • Selpercatinib (TRT A) vs Cabozantinib or Vandetanib (TRT B) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.280 · 95% CI 0.165 to 0.475Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).
SecondaryTreatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)

TFFS by BICR is defined as the time from randomization to the first occurrence of: * documented radiographic disease progression per RECIST 1.1 as assessed by BICR; or * unacceptable toxicity leading to treatment discontinuation as assessed by the investigator. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. To qualify as an event, the toxicity must be from an intolerable AE (defined as any study drug-related AE that meets protocol guidance for treatment discontinuation, with the exception of alopecia); or death (due to any cause).

Time frame:
Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months
Reported as:
Median · Months
Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)
MonthsSelpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)
Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)NA (NA to NA)13.93 (11.27 to 25.10)
Statistical analysis
  • Selpercatinib (TRT A) vs Cabozantinib or Vandetanib (TRT B) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.254 · 95% CI 0.153 to 0.423Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).
SecondaryOverall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR

ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR.

Time frame:
Baseline through Disease Progression or Death Up to 39 Months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR
Percentage of ParticipantsSelpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR69.4 (62.4 to 75.8)38.8 (29.1 to 49.2)
Statistical analysis
  • Selpercatinib (TRT A) vs Cabozantinib or Vandetanib (TRT B) · Clopper-Pearson method · p = <0.0001 (Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib)) · Odds ratio (or): 3.7 · 95% CI 2.2 to 6.3
SecondaryDuration of Response (DoR) by BICR

DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 39 Months
Reported as:
Median · Months
Duration of Response (DoR) by BICR
MonthsSelpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)
Duration of Response (DoR) by BICRNA (NA to NA)16.56 (10.41 to NA)
Statistical analysis
  • Selpercatinib (TRT A) vs Cabozantinib or Vandetanib (TRT B) · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.275 · 95% CI 0.129 to 0.587Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from randomization until death from any cause. If the participant is alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.

Time frame:
Baseline

Results for this outcome have not been posted.

SecondaryPFS2 by Investigator

Progression-free survival 2 (PFS2) is defined as the time from randomization to disease progression (radiographic or symptomatic progression as determined by the investigator) on the next line of treatment or death from any cause in the absence of observed disease progression. If the participant is alive at the cutoff for analysis, and disease progression has not been observed, PFS2 data will be censored on the latest date of last progression-free assessment or start of the next line of treatment.

Time frame:
Baseline

Results for this outcome have not been posted.

SecondaryComparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)

Comparative tolerability defined as a comparison of the proportion of time on treatment with high side effect bother as assessed by the FACT-GP5. The FACT-GP5 is a single question used to assess the overall bother of the treatment side effects. It is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bother from treatment side effects. Time with high side effect bother (i.e.) score of 3 or 4 is reported here and was derived as follows: cumulative amount of time, in weeks, during which a participant reports high side effect bother divided by the total duration of therapy (weeks), derived as (date of last study treatment dose - date of first study treatment dose + 1) divided by 7.

Time frame:
Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months
Reported as:
Mean · Weeks
Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)
WeeksSelpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)
Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)0.08 ± 0.1690.24 ± 0.304
Statistical analysis
  • Selpercatinib (TRT A) vs Cabozantinib or Vandetanib (TRT B) · Wilcoxon (Mann-Whitney) · p = <0.0001 (Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).) · Mean difference (final values): -0.16 · 95% CI -0.23 to -0.10
SecondaryThe Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
Time frame:
Baseline

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selpercatinib - Treatment A (TRT A)8/193 (4.1%)43/193 (22.3%)184/193 (95.3%)
Cabozantinib or Vandetanib - Treatment B (TRT B)10/97 (10.3%)27/97 (27.8%)96/97 (99%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventSelpercatinib - Treatment A (TRT A)Cabozantinib or Vandetanib - Treatment B (TRT B)
HypertensionVascular disorders2/1934/97
PancreatitisGastrointestinal disorders0/1932/97
PyrexiaGeneral disorders3/1930/97
PneumoniaInfections and infestations3/1930/97
Ovarian cystReproductive system and breast disorders1/780/30
ColporrhaphySurgical and medical procedures1/780/30
Urinary tract infectionInfections and infestations2/1930/97
PolycythaemiaBlood and lymphatic system disorders1/1931/97
Cardiac failureCardiac disorders0/1931/97
Myocardial infarctionCardiac disorders0/1931/97
Most frequent other events
Showing 10 of 78
Most frequent other events
EventSelpercatinib - Treatment A (TRT A)Cabozantinib or Vandetanib - Treatment B (TRT B)
DiarrhoeaGastrointestinal disorders51/19359/97
HypertensionVascular disorders82/19339/97
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders7/19341/97
Aspartate aminotransferase increasedInvestigations46/19337/97
Alanine aminotransferase increasedInvestigations51/19333/97
NauseaGastrointestinal disorders20/19331/97
Dry mouthGastrointestinal disorders61/19310/97
Weight decreasedInvestigations10/19327/97
Decreased appetiteMetabolism and nutrition disorders23/19327/97
Mucosal inflammationGeneral disorders14/19325/97

Baseline characteristics

All randomized participants, even if a participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

Age, Categorical
Age, Categorical(Participants)Selpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)Total
<=18 years101
Between 18 and 65 years14372215
>=65 years492675
Sex: Female, Male
Sex: Female, Male(Participants)Selpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)Total
Female7830108
Male11568183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)Total
Hispanic or Latino314
Not Hispanic or Latino9312
Unknown or Not Reported18194275
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)Total
American Indian or Alaska Native000
Asian432467
Native Hawaiian or Other Pacific Islander000
Black or African American527
White11652168
More than one race000
Unknown or Not Reported292049
Region of Enrollment
Region of Enrollment(Participants)Selpercatinib (TRT A)Cabozantinib or Vandetanib (TRT B)Total
United States11415
Czechia606
Japan516
United Kingdom9312
India9211
Russia15621
Spain9312
Greece314
Canada112
Netherlands639
South Korea10212
Belgium101
China141630
Taiwan415
Brazil201333
Poland151025
Italy14620
Israel101
Australia9211
France241842
Germany7613
08

Study locations

143 sites

Showing the first 100 of 143 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Payakachat N, Gilligan AM, Altman D, Maeda P, Choi J, Bourke S, Speck RM, Spies E, Kopeckova K, Elisei R, Wadsley J, Krajewska J. Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5. J Geriatr Oncol. 2025 Sep;16(7):102304. doi: 10.1016/j.jgo.2025.102304. Epub 2025 Jul 4. PubMed 40617171 ↗
  • Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. PubMed 37870969 ↗
  • Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15. PubMed 35969032 ↗
  • Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):540-546. doi: 10.1097/MED.0000000000000662. PubMed 34292174 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in May 2023, 39 months.

Results were first posted in Jun 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2019
First posted
Dec 26, 2019
StartActual
Feb 11, 2020
Primary completionActual
May 22, 2023
CompletionEst.
Nov 2027
Results first posted
Jun 13, 2024
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04211337
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Feb 11, 2020
Primary completion
May 22, 2023
Completion
Nov 2027 (estimated)
Results posted
Jun 13, 2024
Last update
Mar 19, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion